The 8 most recent market catalysts affecting $DGX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 75
CMS Targets $1 Billion in Annual Savings With new Medicare Lab Payment Rates — Here’s What Could Change in 2027
CMS is proposing to reduce Medicare payments for laboratory services by an estimated $1 billion annually, bringing them closer to private-sector rates. This is a significant develo…
Sep 21, 2026
Corporate Catalyst
Neutral
Impact 55
Quest Diagnostics Study Indicates That Nearly One In Three Patients With Antibodies Against Bacterium That Causes Lyme Disease Also Had Antibodies Against One Or More Additional Tick-Borne Pathogens
Quest Diagnostics (DGX) released a study indicating that nearly 30% of patients with Lyme disease antibodies also have antibodies for other tick-borne pathogens. This finding is si…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Mizuho Maintains Outperform on Quest Diagnostics, Raises Price Target to $260
Mizuho analyst Ann Hynes maintained an 'Outperform' rating on Quest Diagnostics (DGX) and raised the price target from $235 to $260. This analyst action signals continued confidenc…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 55
Barclays Maintains Overweight on Quest Diagnostics, Raises Price Target to $250
Barclays analyst Luke Sergott maintained an 'Overweight' rating on Quest Diagnostics (DGX) and raised the price target from $230 to $250. This action signals continued confidence f…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
Quest Diagnostics (DGX) delivered a significant beat on its Q2 earnings and revenue, surpassing analyst consensus. This strong performance was fueled by a 13.1% increase in total r…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Quest Diagnostics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 guidance above estimates.
This headline is a significant corporate catalyst for Quest Diagnostics (DGX), indicating strong fundamental performance and an optimistic future outlook. The better-than-expected …
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 92
Quest Diagnostics Q2 Adj. EPS $3.12 Beats $2.83 Estimate, Sales $3.043B Beat $2.973B Estimate
Quest Diagnostics (DGX) announced Q2 adjusted EPS of $3.12, surpassing the $2.83 consensus estimate by over 10%. Additionally, quarterly sales reached $3.043 billion, exceeding the…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.